Metrics to compare | 493280 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship493280PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −9.3x | −0.4x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | 0.0x | 7.1x | 3.1x | |
Upside (Analyst Target) | 0.0% | 14.8% | 48.4% | |
Fair Value Upside | Unlock | 22.9% | 6.5% | Unlock |
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. IMBiologics Corp. was founded in 2020 and is based in Suwon-si, South Korea.